Nautilus Biotechnology (NAUT) Receivables - Net (2026)
Nautilus Biotechnology (NAUT) posted Receivables - Net of $100000.0 for Q2 2026.
Nautilus Biotechnology (NAUT) Receivables - Net (2026) Analysis & Trends
Nautilus Biotechnology has reported Receivables - Net for 1 years, with the latest figure at $100000.0 in Q2 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - |
| 10 | Nautilus Biotechnology | 123.31 Mn | 123.31 Mn | 175,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Jun 30, 2026 | 100,000.00 |